Four Decades of Orphan Drugs and Priorities for the Future
New England Journal of Medicine · 2024
DOI: 10.1056/nejmp2401487 ↗Kurz gefasst
Historischer Beitrag in der Zeitschrift New England Journal of Medicine, 2024. Verfasst von Michael S Sinha und 2 weiteren Autor:innen. Beteiligte Einrichtung: From the Center for Health Law Studies, Saint Louis University School of Law, St. Louis (M.S.S.); Harvard Business School and the Harvard-MIT Center …. Hauptthemen laut MEDLINE: Orphan Drug Production, Rare Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- From the Center for Health Law Studies, Saint Louis University School of Law, St. Louis (M.S.S.); Harvard Business School and the Harvard-MIT Center for Regulatory Science - both in Boston (A.D.S.); Hasso Plattner Insti…
ORCID-Profile: Michael S Sinha, Ariel D Stern
Zitieren
APA
Sinha, M. S., Stern, A. D., & Rai, A. K. (2024). Four Decades of Orphan Drugs and Priorities for the Future. New England Journal of Medicine. https://doi.org/10.1056/nejmp2401487
Vancouver
Sinha MS, Stern AD, Rai AK. Four Decades of Orphan Drugs and Priorities for the Future. New England Journal of Medicine. 2024. doi:10.1056/nejmp2401487
BibTeX
@article{Sinha2024,
author = {Sinha, Michael S and Stern, Ariel D and Rai, Arti K},
title = {Four Decades of Orphan Drugs and Priorities for the Future},
journal = {New England Journal of Medicine},
year = {2024},
doi = {10.1056/nejmp2401487}
}
EUVIMED